$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000145368717000053 Filed on August 11, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$27.00K	$26.00K	$2.017M
YoY Change	-97.42%	-98.71%	63.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.380M	$4.900M	$2.420M
YoY Change	75.2%	102.48%	8.04%
% of Gross Profit
Research & Development	$9.504M	$10.99M	$6.000M
YoY Change	57.85%	83.23%	12.99%
% of Gross Profit
Depreciation & Amortization	$200.0K	$200.0K	$200.0K
YoY Change	100.0%	0.0%	-56.52%
% of Gross Profit
Operating Expenses	$13.88M	$15.90M	$8.418M
YoY Change	63.0%	88.85%	11.47%
Operating Profit	-$13.85M	-$15.87M	-$6.401M
YoY Change	85.51%	147.95%
Interest Expense	$268.0K	$279.0K	$310.0K
YoY Change	-13.83%	-10.0%	-160.78%
% of Operating Profit
Other Income/Expense, Net	-$16.00K	$0.00	-$64.00K
YoY Change	-500.0%	-100.0%	60.0%
Pretax Income	-$14.68M	-$15.97M	-$6.920M
YoY Change	89.91%	130.78%	0.73%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$14.68M	-$15.97M	-$6.923M
YoY Change	89.91%	130.64%	0.82%
Net Earnings / Revenue	-54355.56%	-61411.54%	-343.23%
Basic Earnings Per Share
Diluted Earnings Per Share	-$664.9K	-$849.0K	-$2.084M
COMMON SHARES
Basic Shares Outstanding	22.07M shares	18.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$104.4M	$112.7M	$84.50M
YoY Change	31.65%	33.37%
Cash & Equivalents	$72.15M	$82.63M	$82.65M
Short-Term Investments	$32.20M	$30.00M	$1.900M
Other Short-Term Assets	$3.000M	$1.900M	$2.500M
YoY Change	-16.67%	-24.0%
Inventory
Prepaid Expenses
Receivables	$0.00	$1.000K	$2.000M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$107.4M	$114.6M	$89.00M
YoY Change	28.72%	28.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.055M	$2.131M	$2.000M
YoY Change	-0.53%	6.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$300.0K
YoY Change		-100.0%
Total Long-Term Assets	$2.371M	$2.447M	$2.300M
YoY Change	-0.46%	6.39%
TOTAL ASSETS
Total Short-Term Assets	$107.4M	$114.6M	$89.00M
Total Long-Term Assets	$2.371M	$2.447M	$2.300M
Total Assets	$109.7M	$117.0M	$91.30M
YoY Change	27.91%	28.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.519M	$4.280M	$900.0K
YoY Change	46.06%	375.56%
Accrued Expenses	$6.547M	$8.595M	$4.400M
YoY Change	168.98%	95.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$4.600M	$1.800M
YoY Change	-100.0%	155.56%
Total Short-Term Liabilities	$11.32M	$20.05M	$8.900M
YoY Change	47.23%	125.31%
LONG-TERM LIABILITIES
Long-Term Debt	$21.00M	$5.700M	$10.10M
YoY Change	130.77%	-43.56%
Other Long-Term Liabilities	$1.250M	$1.250M	$3.500M
YoY Change		-64.29%
Total Long-Term Liabilities	$1.250M	$1.250M	$13.60M
YoY Change		-90.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.32M	$20.05M	$8.900M
Total Long-Term Liabilities	$1.250M	$1.250M	$13.60M
Total Liabilities	$44.65M	$38.84M	$22.50M
YoY Change	119.55%	72.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$197.4M	-$182.7M
YoY Change	43.54%
Common Stock	$2.000K	$1.000K
YoY Change	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.08M	$78.18M	$68.80M
YoY Change
Total Liabilities & Shareholders Equity	$109.7M	$117.0M	$91.30M
YoY Change	27.91%	28.18%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$14.68M	-$15.97M	-$6.923M
YoY Change	89.91%	130.64%	0.82%
Depreciation, Depletion And Amortization	$200.0K	$200.0K	$200.0K
YoY Change	100.0%	0.0%	-56.52%
Cash From Operating Activities	-$15.44M	-$8.610M	-$5.600M
YoY Change	182.27%	53.75%	29.93%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	-$400.0K	-$60.00K
YoY Change	-57.14%	566.67%	-86.05%
Acquisitions
YoY Change
Other Investing Activities	-$2.240M	$11.09M	$6.930M
YoY Change	-88.77%	60.03%
Cash From Investing Activities	-$2.380M	$10.70M	$6.870M
YoY Change	-88.22%	55.75%	-1697.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.340M	53.94M	64.19M
YoY Change	211.02%	-15.97%	895.19%
NET CHANGE
Cash From Operating Activities	-15.44M	-8.610M	-5.600M
Cash From Investing Activities	-2.380M	10.70M	6.870M
Cash From Financing Activities	7.340M	53.94M	64.19M
Net Change In Cash	-10.48M	56.03M	65.46M
YoY Change	-55.06%	-14.41%	3728.07%
FREE CASH FLOW
Cash From Operating Activities	-$15.44M	-$8.610M	-$5.600M
Capital Expenditures	-$120.0K	-$400.0K	-$60.00K
Free Cash Flow	-$15.32M	-$8.210M	-$5.540M
YoY Change	195.18%	48.19%	42.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22074378	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2016Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	420000	USD
CY2017Q2	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	351000	USD
CY2016Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	170000	USD
CY2017Q2	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1723000	USD
CY2016Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	152000	USD
CY2017Q2	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	180000	USD
CY2016Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	245000	USD
CY2017Q2	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	1475000	USD
CY2016Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	29000	USD
CY2017Q2	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	57000	USD
CY2016Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	794000	USD
CY2017Q2	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2448000	USD
CY2016Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	300000	USD
CY2017Q2	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	300000	USD
	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-204000	USD
	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	0	USD
	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	1372000	USD
	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
CY2016	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	4324000	USD
	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
	selb	Proceeds From Vesting Of Restricted Stock ProceedsFromVestingOfRestrictedStock	0	USD
	selb	Stock Issued During Period Value Conversion Preferred Stock Warrants StockIssuedDuringPeriodValueConversionPreferredStockWarrants	47160000	USD
CY2017Q2	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3882000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	265297000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1558000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	649000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1558000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2227333	shares
	selb	Proceeds From Vesting Of Restricted Stock ProceedsFromVestingOfRestrictedStock	10000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4280000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	215000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-160000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3921000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8595000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3740000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4152000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4518000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4413000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211125000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2320166	shares
CY2016Q4	us-gaap	Assets Assets	89301000	USD
CY2017Q2	us-gaap	Assets Assets	117025000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	86816000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	114578000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	24785000	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	30025000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2017Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24821000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	30035000	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	30000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24821000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	30035000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24785000	USD
CY2017Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	30025000	USD
CY2017Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	23	position
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32337000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82648000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82630000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	50311000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58656000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23974000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3164965	shares
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3947900	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18438742	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22056147	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18438742	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22056147	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6753000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13998000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30996000	USD
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	10126118	shares
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2826000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	222000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	189000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1836000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2566000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12439000	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	11619000	USD
CY2016Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	364000	USD
	us-gaap	Depreciation Depreciation	400000	USD
CY2017Q2	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	400000	USD
	us-gaap	Depreciation Depreciation	386000	USD
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.75
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.90
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.67
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	262000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	80000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1551000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1665000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-158000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-378000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	82000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-83000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2418000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4799000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4903000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8778000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-338000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-656000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	1351000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-704000	USD
CY2017Q2	us-gaap	Interest Payable Current InterestPayableCurrent	69000	USD
CY2016Q2	us-gaap	Investment Income Net InvestmentIncomeNet	10000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	23000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-215000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	127000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5636000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	933000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-90000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	537000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2254000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1137000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	310000	USD
	us-gaap	Interest Expense InterestExpense	620000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	279000	USD
	us-gaap	Interest Expense InterestExpense	579000	USD
	us-gaap	Interest Paid InterestPaid	486000	USD
	us-gaap	Interest Paid InterestPaid	461000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81000	USD
CY2017Q2	us-gaap	Investment Income Net InvestmentIncomeNet	101000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	214000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	34344000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	38843000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89301000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	117025000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13706000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20053000	USD
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	4067000	USD
CY2017Q2	us-gaap	Loans Payable Current LoansPayableCurrent	4612000	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	7977000	USD
CY2017Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	5732000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	25000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62508000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53654000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3314000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5834000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15773000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23926000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14399000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-15967000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31101000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9133000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18965000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15967000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31101000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	8418000	USD
	us-gaap	Operating Expenses OperatingExpenses	17447000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	15897000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13342000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15871000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30653000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4200000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1244000	USD
	us-gaap	Operating Expenses OperatingExpenses	30816000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6401000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	335000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1330000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1291000	USD
CY2016Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2017Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	479000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	627000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	170000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	401000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-43000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	80000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	25000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1250000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-82000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	108000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	204000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2650000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	202000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	459000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	32522000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2382000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1848000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	65100000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	49986000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	3516000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	27147000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	504000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5787000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	48000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6283000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2047000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2131000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	75000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151576000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151600000	USD
CY2017Q2	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	26000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1836000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6000000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12648000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10994000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22038000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	78000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	74000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2017Q2	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-182700000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-182677000	USD
CY2016Q2	us-gaap	Revenues Revenues	2017000	USD
	us-gaap	Revenues Revenues	4105000	USD
CY2017Q2	us-gaap	Revenues Revenues	26000	USD
	us-gaap	Revenues Revenues	163000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22056147	shares
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	25485000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	30025000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	5000000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	503000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	54957000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	78182000	USD
CY2016Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	3.9
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4566000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2016Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2210000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4566000	USD
CY2017Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.1000
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	28804969	shares
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	37835623	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3322546	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2749105	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18814570	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18645339	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained approximately </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> in Russian bank accounts, of which </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> was held in U.S. dollars.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has minimal credit risk as the majority of accounts receivable relates to amounts due under a government sponsored grant, collaboration with large pharmaceutical companies or grants from well‑known and supported non‑profit organizations. The Company did not have any off balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation, income taxes, collectability of accounts receivable, useful lives of long-lived assets, accrued expenses, and accounting for project development. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s management made significant estimates and assumptions in determining the fair value of its common stock for those periods reported prior to the completion of the initial public offering of the Company’s common stock (the “IPO”). The Company utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that require the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of its preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</font></div></div>

Files In Submission

Name	View Source	Status
0001453687-17-000053-index-headers.html	Edgar Link	pending
0001453687-17-000053-index.html	Edgar Link	pending
0001453687-17-000053.txt	Edgar Link	pending
0001453687-17-000053-xbrl.zip	Edgar Link	pending
exhibit106_63017.htm	Edgar Link	pending
exhibit107_63017.htm	Edgar Link	pending
exhibit311_63017.htm	Edgar Link	pending
exhibit312_63017.htm	Edgar Link	pending
exhibit321_63017.htm	Edgar Link	pending
exhibit322_63017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20170630.xml	Edgar Link	completed
selb-20170630.xsd	Edgar Link	pending
selb-20170630_cal.xml	Edgar Link	unprocessable
selb-20170630_def.xml	Edgar Link	unprocessable
selb-20170630_lab.xml	Edgar Link	unprocessable
selb-20170630_pre.xml	Edgar Link	unprocessable
selectabiosciences10-q63017.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2017 Q3 Form 10-Q Financial Statement

#000145368717000053 Filed on August 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2017 Q3 Form 10-Q Financial Statement

#000145368717000053 Filed on August 11, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac